1. Think of it as an early-stage Alnylam Pharmaceuticals, developing gene therapies using RNA interference technology.

2. Like a startup Sarepta Therapeutics, focused on tackling genetic diseases with gene therapy, specifically utilizing RNA interference.

• BB-301: An adeno-associated virus based gene therapy agent designed for treating oculopharyngeal muscular dystrophy.
• BB-103: A therapeutic under development for the treatment of chronic hepatitis B virus infection.

Benitec Biopharma (BNTC) Major Customers

Benitec Biopharma Inc. (BNTC) is a development-stage biotechnology company focused on the research and development of novel genetic medicines. The company is currently engaged in advancing its drug candidates, BB-301 for oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection, through clinical development.

As a development-stage company, Benitec Biopharma does not currently have commercial products available for sale. Therefore, it does not have traditional major customers, either other companies or individuals, purchasing its products or services in the commercial marketplace. Its primary activities involve research, development, and clinical trials aimed at bringing its therapeutic candidates to potential future commercialization.

Jerel Banks, M.D., Ph.D. Chief Executive Officer & Chairman of the Board

Dr. Jerel Banks has served as a Director of Benitec Biopharma since October 2016, Chairman of the Board since October 2017, and Chief Executive Officer since June 2018. Prior to his tenure at Benitec, Dr. Banks was the Chief Investment Officer of Nant Capital, LLC. He also held roles as vice president, portfolio manager, and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015, and as a biotechnology equity research analyst at Sectoral Asset Management and Apothecary Capital. His background in investment management at various firms, including a family investment office, and the significant institutional ownership in Benitec by firms like Suvretta Capital and Franklin Resources, align with a pattern of managing companies backed by private equity or institutional investment.

Megan Boston Chief Financial Officer & Director

Megan Boston was confirmed as Chief Financial Officer and Company Secretary, effective January 1, 2025. She has served as a Director of Benitec since August 2016 and as Executive Director since June 2018. Ms. Boston has a track record of serving as Chief Executive Officer and Managing Director for several companies, including those listed on the Australian Stock Exchange, such as Omni Market Tide Ltd and Rision Ltd from 2014 until she joined Benitec. Her experience also includes senior executive roles in risk and compliance at various banking institutions and work at PricewaterhouseCoopers.

Sophie Mukadam Chief Operating Officer

Sophie Mukadam was appointed Chief Operating Officer, effective January 1, 2025. She has been with Benitec since May 2019, serving as Associate Director, Program Management since 2021, and previously as Senior Program Manager. Before joining Benitec, Ms. Mukadam gained extensive scientific research experience between 2003 and 2018 at companies including Genentech (A Member of the Roche Group), Bristol-Myers Squibb, and Pfizer. She also worked as a regulatory affairs professional at Premier Consulting.

The key risks for Benitec Biopharma (BNTC), a development-stage biotechnology company focused on novel genetic medicines, primarily revolve around the inherent challenges of drug development and commercialization.

1. Clinical Trial Outcomes and Regulatory Approval: Benitec Biopharma's success is highly dependent on the successful completion of clinical trials, particularly for its lead product candidate, BB-301, and subsequent regulatory approvals. There is an inherent high risk of failure in drug development, with many trials facing potential setbacks due to inadequate design or execution. Even with promising early data, there is no guarantee of success in later phases or receiving approval from regulatory bodies like the FDA. Specific concerns include the potential for safety issues in higher-dose cohorts and the uncertainty surrounding fully defined regulatory endpoints.

2. Financial Challenges and Capital Needs: As a development-stage company, Benitec Biopharma currently reports no revenue, experiences ongoing operating losses, and has negative earnings per share. While the company has reported a substantial cash position and sufficient cash runway for the near term, there is a significant risk of needing additional financing as clinical development progresses and the burn rate potentially accelerates. Access to capital remains a major challenge for many early-stage biotechnology firms, and any future equity offerings could lead to dilution for existing shareholders.

3. Competition and Market Commercialization: Even upon achieving regulatory approval, Benitec Biopharma faces considerable challenges related to market adoption, intense competition from other gene therapy approaches (e.g., uniQure), pricing pressures, and the ability to secure favorable reimbursement for its products. Commercializing services and products is the ultimate goal, but obstacles such as slow market penetration and a lack of reimbursement can significantly impact a biotechnology company's success.

Benitec Biopharma Inc. (BNTC) is a clinical-stage biotechnology company primarily focused on developing novel genetic medicines, with its lead product candidate, BB-301, targeting oculopharyngeal muscular dystrophy (OPMD). As a development-stage company, its future revenue growth over the next 2-3 years is contingent upon the successful progression and commercialization of its pipeline assets, particularly BB-301.

The key expected drivers of future revenue growth for Benitec Biopharma over the next 2-3 years include:

1. Successful Late-Stage Clinical Development of BB-301 for OPMD: The continued positive advancement of BB-301 through pivotal clinical trials is a fundamental driver. Benitec Biopharma has reported promising interim results from its Phase 1b/2a clinical trial, demonstrating significant and durable improvements in dysphagia for OPMD patients. The company plans to engage with the U.S. Food and Drug Administration (FDA) in mid-2026 to finalize the pivotal study design for BB-301, which is a critical step towards generating the necessary data for regulatory submission. Positive outcomes from these late-stage trials will be essential to de-risk the asset and move closer to market.
2. Securing Regulatory Approvals for BB-301 in OPMD: The receipt of regulatory approvals from authorities such as the FDA and the European Medicines Agency (EMA) for BB-301 would be a direct trigger for future revenue. BB-301 has already received Orphan Drug Designation from both the EMA and FDA, as well as Fast Track Designation from the FDA, which could expedite its development and review process. While analysts project zero revenue for BNTC in 2026, some forecast substantial revenue for 2027 and 2028, implying that regulatory approval and subsequent market entry are anticipated within this timeframe.
3. Commercial Launch and Market Penetration of BB-301: Upon successful regulatory approval, the commercial launch and subsequent market penetration of BB-301 in the OPMD market are expected to drive revenue growth. OPMD currently has no approved disease-modifying therapies, representing a significant unmet medical need. As potentially the first approved therapy, BB-301 could capture a substantial share of the market, which is estimated to be significant, with global projections reaching up to $25.33 billion by 2037. This first-mover advantage and the addressing of an unmet need position BB-301 as a significant potential revenue generator for Benitec Biopharma.

Share Issuance

• In April 2021, Benitec Biopharma increased a bought deal offering of common stock to approximately $12.9 million.
• The company completed a 1-for-17 reverse stock split in July 2023 to enhance share liquidity.
• In November 2025, Benitec concluded an equity financing that grossed approximately $100 million before deducting costs, through an oversubscribed public offering of common stock, which included an underwritten public offering of 5.93 million shares and a concurrent registered direct offering of 1.48 million shares to Suvretta Capital, both priced at $13.50 per share.

Inbound Investments

• Suvretta Capital Management, LLC participated in the November 2025 equity financing, acquiring 1.48 million shares through a registered direct offering.
• Between December 18 and December 22, 2025, Suvretta Capital Management, LLC, along with affiliated entities, purchased Benitec Biopharma shares totaling $538,972.
• In Q4 2025, several institutional investors, including Nantahala Capital Management LLC, Alyeska Investment Group L.P., and Siren L.L.C., acquired or increased significant positions in the company's stock.

Outbound Investments

• Benitec Biopharma has acquired Tacere Therapeutics.

Capital Expenditures

• For the fiscal year ended June 30, 2024, capital expenditures were $0.18 million.
• In the quarter ended December 31, 2025 (Q2 2026), Benitec Biopharma invested $11 in capital expenditures.
• Over the last 12 months, capital expenditures were -$17,000.